1. Home
  2. CDIO vs MBRX Comparison

CDIO vs MBRX Comparison

Compare CDIO & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardio Diagnostics Holdings Inc.

CDIO

Cardio Diagnostics Holdings Inc.

N/A

Current Price

$1.65

Market Cap

6.1M

Sector

Health Care

ML Signal

N/A

Logo Moleculin Biotech Inc.

MBRX

Moleculin Biotech Inc.

N/A

Current Price

$8.00

Market Cap

6.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CDIO
MBRX
Founded
2017
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Commercial Physical & Biological Resarch
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.1M
6.4M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
CDIO
MBRX
Price
$1.65
$8.00
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $240.00
AVG Volume (30 Days)
14.9K
★ 30.2K
Earning Date
12-01-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $14,825.00
N/A
Revenue This Year
$168,534.06
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.97
$0.16
52 Week High
$7.91
$11.14

Technical Indicators

Market Signals
Indicator
CDIO
MBRX
Relative Strength Index (RSI) 41.69 67.76
Support Level $1.53 $2.12
Resistance Level $2.20 $10.24
Average True Range (ATR) 0.13 0.73
MACD -0.00 -0.33
Stochastic Oscillator 12.87 88.68

Price Performance

Historical Comparison
CDIO
MBRX

About CDIO Cardio Diagnostics Holdings Inc.

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Share on Social Networks: